RUEIL MALMAISON
Marc de Gasparo, MD is the founder of MG Consulting Co. He received a medical degree from the Catholic University of Louvain, was a research fellow at the Medical Clinic at University Hospital in Louvain and had clinical training at the Gestational Endocrinopathy Outpatient Clinic. After working in the Department of Biochemistry at the University of California, San Francisco, Dr. de Gasparo joined the Research Department of the Pharmaceutical Division of Ciba-Geigy, Basel, where he first described the selective aldosterone receptor antagonist eplerenone. In addition, he first reported the existence of two angiotensin II receptor subtypes and developed valsartan, a non-peptidic angiotensin II receptor antagonist. He also described the involvement of tyrosine phosphatases in the signaling mechanism of the AT2 receptor. Dr. de Gasparo is the author of more than 190 publications in the fields of diabetes mellitus, insulin chemistry, developmental biochemistry, hypertension, and the renin-angiotensin-aldosterone system including 3 chapters in books on Hypertension. Retired from Novartis, he is still active in these fields, advising various pharmaceutical companies, writing, lecturing and editing. Until Dec 2004, he chaired the IUPHAR subcommittee for the nomenclature of the angiotensin receptor, is a member of the Editorial Board of the Journal of Cardiovascular Pharmacology and regular reviewer for various journals.
Mes compétences :
Diabète
Hypertension
Pharmacologie
Pas de formation renseignée
